ihl_logo.png
Incannex Receives Ethics Approval for Bioequivalence/Bioavailability Clinical Trial for IHL-42X, the Company’s Proprietary Drug for Treatment of Obstructive Sleep Apnoea (‘OSA’)
July 06, 2023 08:42 ET | Incannex Healthcare
Highlights: Incannex has received approval from Bellberry Human Research Ethics Committee (‘HREC’) to commence the bioavailability/bioequivalence (‘BA/BE’) clinical trial to assess the...
22157.jpg
Global Large Molecule Bioanalytical Testing Services Market Report 2022 to 2029: Featuring Charles River, Medpace, WuXi AppTec and Eurofins Scientific Among Others
December 01, 2022 06:33 ET | Research and Markets
Dublin, Dec. 01, 2022 (GLOBE NEWSWIRE) -- The "Large Molecule Bioanalytical Testing Services Market Analysis by Phase, by Type, by Test Type, by Therapeutic Area, by End user by Region - Global...
Global Bioanalytical Testing Services Market
Global Bioanalytical Testing Services Market (2022 to 2030) - Size, Share & Trends Analysis Report
February 22, 2022 07:23 ET | Research and Markets
Dublin, Feb. 22, 2022 (GLOBE NEWSWIRE) -- The "Bioanalytical Testing Services Market Size, Share & Trends Analysis Report by Molecule (Small, Large), by Test (Bioavailability, Bioequivalance),...
22157.jpg
Global $6.34 Bn Bioanalytical Testing Services Markets to 2028 - Increasing Outsourcing Services & Rising Investments in the Sector
November 23, 2021 05:28 ET | Research and Markets
Dublin, Nov. 23, 2021 (GLOBE NEWSWIRE) -- The "Bioanalytical Testing Services Market Share, Size, Trends, Industry Analysis Report, By Molecule Type (Small Molecule, Large Molecule); By Test Type;...
Figure 1
Minerva Neurosciences Announces Study Results Demonstrating Bioequivalence of Phase 2b, Phase 3, and Planned Commercial Formulations of Roluperidone for Treatment of Negative Symptoms of Schizophrenia
September 30, 2021 08:30 ET | Minerva Neurosciences, Inc
WALTHAM, Mass., Sept. 30, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Certara Logo White Background.png
Certara Awarded FDA Grant to Further Advance Virtual Bioequivalence Assessments of Generic Medicines Using Biosimulation
September 20, 2021 08:00 ET | Certara
PRINCETON, N.J., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Certara (Nasdaq: CERT), a global leader in biosimulation, today announced the Company has been awarded a grant from the U.S. Food and Drug...
22157.jpg
Global Large Molecule Bioanalytical Testing Services Market Report 2021: Increased Applications in Clinical Trials of Biomarkers & Large Molecules
August 24, 2021 08:13 ET | Research and Markets
Dublin, Aug. 24, 2021 (GLOBE NEWSWIRE) -- The "Global Large Molecule Bioanalytical Testing Services Market Size, Share & Trends Analysis Report by Phase (Preclinical, Clinical), by Test Type...
Elite Pharmaceuticals, Inc. Logo
Elite Pharmaceuticals Reports Positive Topline Results from Pivotal Bioequivalence Studies for an Extended-Release Generic
January 10, 2018 08:00 ET | Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Jan. 10, 2018 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB:ELTP) today reported positive topline results from pivotal bioequivalence studies for...
Elite Pharmaceuticals, Inc. Logo
Elite Pharmaceuticals Reports Successful Pivotal Bioequivalence Study for Abuse Deterrent Product ELI-200
March 05, 2014 07:30 ET | Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., March 5, 2014 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP) announced today successful results from a pivotal bioequivalence study initiated...